Abbott’s 3Q $8.9Bn Sales Beat Wall Street Consensus, Medtech Sales Up 3.4%
Abbott reported strong sales for diagnostics and devices in the third quarter and raised its full-year EPS guidance to $3.55 per share.
You may also be interested in...
Abbott will commit $5m to support the ADA’s efforts to bring diabetes technologies and education to underserved diabetes populations.
Boston Scientific’s management believes the ongoing recovery of procedure volumes and new technology will allow it to show revenue growth in the fourth quarter.
The FDA has granted an emergency use authorization for a COVID-19 IgM antibody blood test that runs on Abbott’s Architect and Alinity platforms.